ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Palliative and end-of-life care · Support Care Cancer · 2026-11-13

Secondary analysis of the SUCCESS C trial in 1582 women with early HER2-negative breast cancer: eating before chemotherapy was associated with less vomiting on FEC and TC, and less nausea on FEC only, most clearly in the first 24 h.

Secondary analysisn = 1,582
Schäffler et al. Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial
Palliative and end-of-life care · Support Care Cancer · 2026-11-09

Secondary analysis of an RCT in 189 patients with breast cancer: within true electroacupuncture, HTR3A rs909411 GG was linked to more complete protection from chemotherapy nausea and vomiting (62.3%) and COMT rs4633 to less; no SNP-by-treatment interaction.

Secondary analysisn = 189
Zheng et al. Association of HTR3A and COMT polymorphisms with electroacupuncture response for chemotherapy-induced nausea and vomiting in breast cancer: a secondary analysis of a randomized controlled trial
Palliative and end-of-life care · Support Care Cancer · 2026-11-03

In a systematic review and meta-analysis of 10 RCTs (851 cancer survivors given cardiotoxic therapies), home-based exercise improved VO2 peak (MD 2.35 mL/kg/min) but not 6MWT or quality of life; effect on cardiotoxicity was unproven (one study).

Meta-analysisn = 851
Wang et al. Effectiveness of home-based exercise interventions on cardiorespiratory fitness and cancer treatment-related cardiovascular toxicity in cancer survivors exposed to cardiotoxic therapies: a systematic review and meta-analysis of randomized controlled trials
Palliative and end-of-life care · Support Care Cancer · 2026-10-29

In 90 patients after laparoscopic gastric or colorectal cancer surgery, AI-facilitated individualised nutritional guidance with clinician review raised 30-day energy intake adequacy vs standard advice (66.7% vs 40.0%; OR 3.0); no difference in weight, markers or complications.

RCTn = 90
Chen et al. AI-facilitated individualized nutritional guidance with ABC-structured prompts improves short-term dietary intake adequacy and patient-reported symptoms after gastrointestinal cancer surgery: a randomized controlled trial
Palliative and end-of-life care · Support Care Cancer · 2026-10-23

Systematic review of 34 cohort studies (27,473 patients with gastrointestinal cancers): cachexia was associated with postoperative complications (OR 1.38) and longer hospital stay (MD 2.09), not chemotherapy adverse events (OR 1.42, NS). Very low certainty evidence.

Meta-analysisn = 27,473
Furuya et al. Association between cancer cachexia and treatment-related adverse outcomes in patients with gastrointestinal cancers: a systematic review and meta-analysis
Palliative and end-of-life care · Support Care Cancer · 2026-10-22

In 193 patients undergoing breast biopsy, remote monitoring with phone-based or electronic patient-reported outcomes did not change pain at day 4 versus standard care (overall median 0). Secondary: fewer had clinically significant anxiety at day 4 in both monitored arms.

RCTn = 193
Guerdoux et al. Impact of remote management using patient-reported outcomes on pain and anxiety after breast biopsy: the BIO-PSY randomized controlled trial
Palliative and end-of-life care · Support Care Cancer · 2026-10-22

RCT in patients with a colostomy: telephone-based education and counselling led to higher stoma acceptance and total adjustment scores and lower complication severity at 3 months vs routine stoma care; no difference in anxious preoccupation, social engagement or anger.

RCT
Yurtseven et al. The effect of telephone-based education and counselling on stoma adjustment and complication severity in individuals with a colostomy: a randomised controlled trial
Palliative and end-of-life care · Support Care Cancer · 2026-10-19

RCT in 155 children receiving high-dose methotrexate: oral mucositis occurred in 41.1% with intraoral vs 30.5% with extraoral photobiomodulation (p=0.168), with no difference in severity or pain; extraoral sessions took 30 s vs about 6 min.

RCTn = 155
Freitas et al. Comparable efficacy of extraoral and intraoral photobiomodulation in preventing oral mucositis during high-dose methotrexate therapy in pediatric oncology: A single-blind randomized controlled trial
Palliative and end-of-life care · Support Care Cancer · 2026-10-19

Network meta-analysis of 12 RCTs (736 cancer patients): prolonged scalp hypothermia (>90 min) improved hair preservation vs usual care (RR 24.66; 95% CI 7.07–86.05) and traditional cooling (RR 2.13), but not significantly vs short. Low to very low certainty.

Meta-analysisn = 736
Boonpattharatthiti et al. Comparative efficacy of interventions for preventing chemotherapy-induced alopecia: a systematic review and network meta-analysis
Palliative and end-of-life care · Support Care Cancer · 2026-10-10

In 132 patients with breast cancer and sleep disturbance on chemotherapy, 12 weeks of anti-inflammatory dietary education vs usual care lowered PSQI (β −2.10) and sleep disturbance at 12 weeks (49.2% vs 78.9% in 116 completers), and improved quality of life.

RCTn = 132
Cheng et al. Effects of anti-inflammatory dietary education on sleep disturbances among patients with breast cancer undergoing chemotherapy: A randomized controlled trial
Palliative and end-of-life care · Support Care Cancer · 2026-10-06

Meta-analysis of 15 studies (5440 adults with DLBCL on first-line R-CHOP-based therapy): pooled febrile neutropenia incidence was 19.0% in 10 observational cohorts vs 11.7% in 5 heterogeneous trials; the design difference was not significant (p=0.051).

Meta-analysisn = 5,440
Reyes et al. Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence
Palliative and end-of-life care · Support Care Cancer · 2026-10-04

In 106 adults undergoing haematopoietic cell transplantation, N-acetylcysteine mouthwash did not significantly reduce any-grade oral mucositis vs placebo (61.1% vs 73.1%; P=0.190) but reduced severe (grade 3–4) mucositis, the other primary outcome (5.6% vs 25.0%; P=0.006).

RCTn = 106
Tahmasebi et al. N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.